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Background/aim: Autoimmune bullous diseases, if left untreated, are life-threatening conditions affecting primarily skin and mucous
membranes. These blistering disorders are characterized by epidermal or subepidermal detachment. Autoimmunity plays a key role in
pathogenesis; therefore, immunosuppressive agents are the treatment of choice. The aim of this study is to document relative frequencies
of different autoimmune bullous diseases, patient characteristics, treatment options, and side effects in patients presenting to our bullous
skin disease center at İstanbul University, Cerrahpaşa, Cerrahpaşa Medical Faculty.
Materials and methods: Medical files were examined retrospectively for all patients with autoimmune bullous diseases who were
followed up between 2003 and 2019 at the Bullous Skin Disease Center at İstanbul University, Cerrahpaşa.
Results: A total of 346 patient files were examined. Pemphigus vulgaris was the most frequent autoimmune bullous disease, followed
by bullous pemphigoid and pemphigus foliaceus, according to our study. There is a general female predominancy for all autoimmune
bullous diseases. The most commonly preferred treatment options were high-dose daily corticosteroids.
Conclusion: This retrospective study summarizes the patient characteristics, comorbidities, treatment choices, and side effects during
16 years of clinical practice.
Key words: Bullous diseases epidemiology, pemphigus vulgaris, bullous pemphigoid

1. Introduction
Autoimmune bullous diseases (AIBDs) are rare but
potentially devastating disorders of the skin and mucous
membranes, characterized by the presence of tissuebound and circulating antibodies directed against diseasespecific target antigens. Based on the level of blister
formation, these diseases can be divided into 2 groups:
intraepidermal immunobullous diseases, also referred to as
the pemphigus group, and subepidermal immunobullous
disorders. The pemphigus group comprises pemphigus
vulgaris (PV) and its variant pemphigus vegetans,
superficial pemphigus (pemphigus fo
liaceus (PF)
and pemphigus erythematosus (PE)), paraneo
plastic
pemphigus (PNP), and IgA pemphigus. The incidence
of pemphigus ranges from 0.5 to 16.2/1,000,000 per year
[1–5]. The subepidermal immunobullous disorders group
includes pemphigoid diseases (bullous pemphigoid (BP),
mucous membrane/cicatricial pemphigoid (MMP/CP),
pemphigoid gestationis (PG), linear IgA disease (LAD),

and lichen planus pemphigoides (LPP)), epidermolysis
bullosa acquisita (EBA), dermatitis herpetiformis (DH),
and bullous systemic lupus erythematosus (BSLE).
The incidence of BP has been estimated between 2 and
42.8/1,000,000 per year [1,4,6,7].
PV is frequently observed in Turkey, as in other
countries of the Mediterranean region. However, there
has not yet been any study of the relative frequencies and
demographic features of different AIBDs in Turkey. Notably,
the relative frequencies of subepidermal immunobullous
disorders versus those of diseases in the pemphigus group
are unknown. Our aim is to define the spectrum of AIBDs
seen at the Center for Bullous Diseases in the Cerrahpaşa
Medical Faculty, one of the major tertiary referral centers
for AIBDs in Turkey, over a 16-year period.
2. Materials and methods
A retrospective analysis was performed at the Bullous
Disorders Center in the Department of Dermatology and
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Venereology, University Hospital of Cerrahpaşa Medical
Faculty in İstanbul, which is one of the major tertiary care
follow-up and referral centers for patients with bullous
diseases in Turkey. Although there is no systematic
referral system or central registry for AIBDs in Turkey,
this hospital is one of the most preferred tertiary referral
centers, both in terms of public and private hospitals.
All medical files of newly diagnosed patients with
AIBDs were retrospectively recruited and analyzed for
a period of 16 years between 2003 and 2019. Diagnoses
were based on clinical findings, histo
pathology of
affected skin or mucosa, direct immunofluore
scence
(DIF) microscopy of perilesional mucous membrane
or skin biopsies, indirect immunofluorescence (IIF)
microscopy on monkey esophagus, and enzyme-linked
immunosorbent assay (ELISA) for anti-desmoglein 1 and
3 antibodies. Patient inclusion criteria for the retrospective
analysis comprised a diagnosis of AIBD confirmed by
histopathological and direct immunofluorescence (DIF)
examinations of tissue samples, in addition to clinical
findings. Thus, histopathological examination and direct
and indirect immunofluorescence examination were
performed for all the patients included in this study.
Detailed reviews of the patients’ clinical histories,
other autoimmune diseases, and comorbidities of
patients and their relatives, in addition with data about
age, sex, age at onset of the disease, and duration of
the disease were recorded. Clinical status at the onset
such as mucosal and/or cutaneous involvements was
evaluated. Histopathological examination, direct and
indirect immunofluorescence test results, ELISA testing
of antidesmoglein (anti-Dsg) 1 and 3 antibodies for
the pemphigus group, local and systemic treatment
modalities, relapses and remissions, side effects, and
reported deaths during the follow-up period were also
recorded.

3. Results
Between 2003–2019, 346 new cases of AIBDs, 151 men
and 195 women (an average of 23 new cases per year),
were analyzed in this study. The average annual ageadjusted AIBD incidence rate for our center was 0.307
per million in the population for both sexes. The mean
age was 54.4, and mean duration of the disease was
85.6 months. Only 5 of all of these patients had a family
history. The most common diagnoses were PV, BP, and
PF, respectively (70%, 13%, and 6%), all of which seem
to have occurred more commonly in females. Other rare
diagnoses included hereditary epidermolysis bullosa,
pemphigoid gestationis, Hailey–Hailey disease, dermatitis
herpetiformis, subcorneal pustular dermatosis, LPP, and
Grover’s disease. Table 1 summarizes the epidemiological
and clinical characteristics of all AIBDs.
The mean follow-up period for PV patients was 79.9
months, whereas for PF it was 82.8 months and for BP
the total was 75.4 months. The most commonly used
treatment options were high-dose corticosteroids and
immunosuppressives such as azathioprine, mycophenolate
mofetil, or sodium. Plasmapheresis, methotrexate,
cyclosporine, dapsone, and colchicine in the case of
acquired epidermolysis bullosa were less preferred
options. Intravenous immunoglobulin, rituximab and
pulse steroid therapy were commonly used in recalcitrant
cases. For AIBDs, a high-dose daily systemic steroid was
the most preferred treatment, with azathioprine being
the most common adjuvant, as summarized, together
with other treatment options, in Table 2. It is important
to note that the most common adverse events such as
osteoporosis, aseptic bone necrosis and compression
fractures, myopathy, and cataracts are related to high-dose
and long-term use of systemic corticosteroids. Other rare
side effects include depression, diabetes, hypertension,
neuropathy, pancytopenia, glaucoma, hepatotoxicity,

Table 1. Epidemiological and clinical characteristics of all autoimmune bullous disease patients.
RF

F/M

FH

MA

MD

M

C

M&C

PV

242

1.4

1

51.4

77.9

77

30

135

BP

45

1.25

-

75.6

75.4

1

35

9

PF

23

1.09

-

49.4

84

-

23

-

LAD

13

1.6

1

43.7

77

-

12

1

EBA

7

0.75

1

49.4

298

-

4

3

PE

5

-

1

57

171

-

5

-

MMP

4

1

-

67

75

4

-

-

RF: Relative frequency; F/M: Female to male ratio; FH: Family history (n); MA: Mean age (years); MD:
Mean duration of disease (months); M: Only mucosal involvement; C: Only cutaneous involvement; M & C:
Mucosal and cutaneous involvement.
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pneumonia, and steroid acnes. To the best of our
knowledge, a total of 8 deaths were declared during the
follow-up period of these patients; however, there may
have also been some underreporting. Three of the patients
died due to bronchopneumonia, 3 from cardiopulmonary
arrest, and the exact cause of death for the remaining 2
patients remains unknown.
3.1. Pemphigus vulgaris
Two hundred and forty-two patients were diagnosed as PV
(242/346, 70%). Only one of them had a family history.
The female to male ratio was 1.4 (f: 141, m: 101) and the
mean age was 51.4 years. The mean duration of the disease
was 77.9 months. Table 3 summarizes the comorbidities

of PV patients, together with other AIBDs. Approximately
12% of all PV patients (30 patients) presented with only
cutaneous lesions, and 32% (77 patients) of them with only
mucosal lesions, while remaining 135 patients (56%) had
both cutaneous and mucosal involvements. In addition
to systemic treatment modalities, all PV patients received
local treatment, including topical antimicrobials and
local corticosteroid ointments. All patients with mucosal
involvement were also given intralesional triamcinolone
acetonide (20 mg/mL) injections. All PV patients were
started on high-dose systemic corticosteroids immediately
after diagnosis. The mean initial systemic steroid dosage
was 100 mg/day of methylprednisolone or the equivalent,

Table 2. Systemic treatment options for autoimmune bullous skin disorders.
Patients (n)

SS

PS

Aza

MM

MS

IVIg

Rit

Dp

Mtx

PV

242

214

48

214

33

22

42

43

-

4

BP

45

-

1

10

-

-

-

-

6

1

PF

23

21

4

21

3

2

3

2

-

-

LAD

13

7

-

4

-

-

-

1

7

-

EBA

7

5

-

-

-

-

-

-

1

-

PE

5

4

-

4

-

-

-

-

-

-

MMP

4

3

-

1

-

-

-

-

-

-

Total

339

-

53

254

36

24

45

46

14

5

SS: Systemic steroid; PS: Pulse steroid; Aza: Azathioprine; MM: Mycophenolate mofetil; MS: Mycophenolate
sodium; IVIg: Intravenous immunoglobulin; Rit: Rituximab; Dp: Dapsone; Mtx: Methotrexate.
Table 3. Most common comorbidities of pemphigus vulgaris, bullous pemphigus, pemphigus foliaceus, and
pemphigus erythematosus patients.
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Comorbidities

PV patients (n)

BP patients (n)

PF patients (n)

PE patients (n)

Hypertension

17

13

1

1

Diabetes mellitus

10

6

-

1

Hyperlipidemia

6

2

-

-

Osteoporosis

6

1

-

-

Hepatitis

2

2

-

-

Coronary heart disease

2

2

-

1

Cataract

2

4

1

-

Chronic renal failure

1

2

-

-

Hyperthyroidism

1

-

-

-

Benign prostate hyperplasia

2

2

-

1

Rheumatoid arthritis

2

1

1

-

Pulmonary tuberculosis

1

3

-

-

Alzheimer’s disease

-

3

-

-

Parkinson disease

-

1

-

-
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which gradually tapered to maintenance levels in a few
months to years, according to the clinical course and
prognosis of each and every patient. Azathioprine was
the most commonly used adjuvant, with a mean daily
dosage of 150 mg. Mycophenolate mofetil (2000 mg/
day) or mycophenolate sodium (1440 mg/day) were the
second-line adjuvants and were preferred in patients who
could not tolerate azathioprine or had a long-term history
of azathioprine use. Pulse steroid therapy was given
intravenously in divided doses for 3 consecutive days
(1000 mg methylprednisolone per day). It was preferred
in only 48 patients during this 16-year period in case of
frequent relapses or to avoid side effects of long-term
systemic steroids.
Beside physical examination of all skin and mucosal
membranes, follow-up examinations every 3 months
included indirect immunofluorescence titer and
antidesmoglein 1 and 3 antibody levels. Complete blood
count, fasting blood glucose level, and liver and kidney
function tests are also routinely done for detecting
possible adverse events related to treatment. Annual bone
mineral density measurements were also performed.
Approximately 41% of all our patients had at least one
relapse during their long-term follow-ups. The most
common treatment-related adverse events are shown in
Table 4. Throughout the follow-up period, 3 deaths were
reported.
3.1.1. IVIg and rituximab therapy in recalcitrant
pemphigus vulgaris
IVIg was used at a monthly dose of 2 g/kg, which was
divided equally over 5 consecutive days for 3 to 9 months
for refractory PV, alone or in combination with rituximab.
Anti-CD20 monoclonal antibody rituximab was
administered as 1000-mg intravenous infusions, 2 weeks
apart. In our clinic, 59 patients used IVIg and/or rituximab,
55 of which had PV and 4 had PF. Fourteen patients used
rituximab alone, while 13 patients used IVIg alone, and the
remaining 32 patients used both agents in combination. In
the ‘only IVIg’ group, 10 out of 13 patients had clearance
of disease with no recurrence after a mean treatment
duration of 4.3 months. Two patients were able to recover
with IVIg (3 and 5 administrations, respectively), but they
had recurrences 3 years after the treatment period, while
the other patient still had ongoing disease reoccurrence
in spite of 6 treatment courses of IVIg administration. In
the ‘only rituximab’ group, 13 out of 14 patients had no
recurrence after 1 or 2 administrations (2–4 grams in
total). One patient was lost to follow-up. Out of 32 patients
who were using combined therapy, 26 had no recurrences
after a mean duration of 4.2 months. Three patients had
only IVIg treatment for 6 months with limited response
and, after the combination with rituximab, they healed
completely. Two patients had reoccurring symptoms after

Table 4. Most common treatment-related adverse events of
pemphigus vulgaris and bullous pemphigoid patients.
Adverse events

PV patients (n)

BP patients (n)

Osteoporosis

36

4

Hepatotoxicity

13

3

Myopathy

9

2

Cataract

9

5

Diabetes

4

3

Oral candidiasis

3

1

Pancytopenia

3

2

Pneumonia

2

3

Neuropathy

2

-

Avascular necrosis

2

1

Deep vein thrombosis

1

-

1 year of 3 IVIg and one rituximab course, but later on
they responded well to the same treatment regimen. The
remaining patient had refractory disease even after 6
courses of IVIg and one course of rituximab treatment.
It is important to note that 1 patient had an episode of
deep venous thrombosis during the 3rd session of IVIg
infusions, which led to the discontinuation of the therapy.
3.2. Bullous pemphigoid
BP was the 2nd most frequent AIBD in our study, with
45 patients (13%). Among these patients, 35 had only
cutaneous lesions, one of them had only mucosal lesions,
while the remaining 9 patients had both. None of them
had a family history. The female to male ratio was 1.25 (f:
25, m: 20), and the mean age of and mean duration of the
disease were 75.6 years and 75.4 months, respectively. It is
important to note that BP patients were significantly older
than PV patients (mean age: 75.6 years vs. 51.4 years)
with more comorbidity, as shown in Table 3. All patients
received topical treatment as a first-line therapy. Lower
systemic steroid doses (about 0.5 mg/kg/day) are preferred
when compared to PV, with a mean initial dose of 55.4
mg/day of methylprednisolone; tapering to maintenance
levels was done more rapidly. One patient was given due
to long-term side effects of corticosteroids. Azathioprine
(N: 10), dapsone (N: 6), pulse steroid therapy (N: 1), and
methotrexate (N: 1) were adjuvants used for refractory
cases. The main treatment-related side effects in this
patient group are summarized in Table 4. Throughout
the follow-up period, 6 recurrences and 5 deaths were
reported.
3.3. Pemphigus foliaceus
PF was the 3rd most frequent AIBD, with 23 patients. None
of them had a family history. The female to male ratio was
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1.09 (f: 12, m: 11), the mean age was 49.4, and the mean
duration of the disease was 84 months. All of the patients
had only cutaneous involvement, as expected. Two patients
were treated with only topical corticosteroids, due to
limited disease, and the remaining 21 patients were given
high-dose systemic steroids, together with azathioprine.
Two of them were switched to mycophenolate sodium
and 3 to mycophenolate mofetil due to side effects. Three
patients received IVIg, 1 patient received rituximab,
another was given both, and 4 patients received pulse
steroids, due to resistant disease, with successful results.
Ten patients had recurrent attacks during the course of the
disease.
3.4. Other autoimmune bullous skin diseases
One patient was diagnosed with benign familial pemphigus
and treated with topical agents. Four patients (2 males
and 2 females) with mucous membrane pemphigoid were
also treated as PV. Thirteen patients were diagnosed as
having linear IgA disease. Only one of them had mucosal
involvement, while the remainder had cutaneous lesions.
Only one patient had a family history of the disease. The
mean age of the patients was 44.5 years. One patient had
ulcerative colitis, which is the most common disorder
associated with linear IgA bullous dermatosis. Seven
patients were given a combination of dapsone (50–100 mg/
day) and systemic steroids, 3 patients used azathioprine,
1 patient was treated with colchicine, and 1 patient with
rituximab. Of 8 epidermolysis bullosa patients, 5 received
systemic corticosteroids, 1 was given dapsone, 1 received
colchicine, and 1 recalcitrant case was treated with IVIg.
4. Discussion
AIBDs are a group of rare and potentially lethal disorders
characterized by the onset of vesiculobullous lesions on
the skin or mucous membranes, alteration of cutaneous
or mucous membrane components, and presence of
pathogenic autoantibodies targeting structural proteins
of the desmosomes and the dermal-epidermal junction.
Most cases of AIBD occur sporadically, without evidence
of geographic or familial clustering. Little is known about
the epidemiology of AIBD in Turkey. Epidemiologic
surveys encompassing the whole spectrum of AIBDs, not
a single disease or a group of diseases, are also limited in
other countries. This is the first study on the entire group
of AIBDs in Turkey, based on strict diagnostic criteria,
including clinical, histological, and immunohistological
evaluation. The large number of patients and long
observation pe
riod, coupled with the epidemiological
and clinicopathological aspects, treatment modalities,
and side-effect profiles, are the main assets of this study.
On the other hand, the incidence of BP and DH could
have been underestimated due to their atypical and mild
clinical presentation in some individuals. There is an
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overall female predominance in AIBDs, and this female
predominance also applied to individual diseases, except
IgA pemphigus, LAD, and EBA, which involved only a few
patients [8].
4.1. Pemphigus vulgaris
PV is characterized by autoantibodies working against
intercellular adhesion molecules: Dsg3 or both Dsg 1
and 3, resulting in suprabasal acantholytic blisters. Our
present observation confirms the data in previous studies
and adds further support to the earlier notion that the
clinical phenotype of pemphigus correlates with the antiDsg autoantibody profile. As expected, PV was the most
common type of AIBD in our study, representing 70% of
all cases. This finding is in line with reports from other
Mediterranean, Middle Eastern, and East Asian countries
such as Kuwait [6], Iran [8], China [9], Malaysia [10], and
also from other studies from Turkey [11] but contrasts
with reports from countries such as Switzerland, Germany,
the UK, and Singapore, where SABDs, notably BP,
predominated [1,4,12,13]. Compared with epidemiologic
surveys in different regions of the world, the incidence
of PV in İstanbul is very similar to that of neighboring
countries such as Macedonia [2], Romania [3], Bulgaria
[14], and Kuwait [6]. While the incidence is higher than in
Western European countries such as Switzerland and the
United Kingdom [1,12,15–17], it is lower than the rate in
Iran [5,18], Tunisia [17], Greece [19], as well as rates found
in Jewish individuals in the US [20]. The incidence of PV
has been estimated to be 0.76, 0.77, and 1.7 in terms of new
cases per million people per year in Finland, Germany, and
France, respectively [12,16,17]. In contrast, in countries
around the Mediterranean sea, the reported incidence
is significantly higher, with 6, 6.7, and 8 new cases per
million people per year in Eastern Sicily, Tunisia, and
Northern Greece, respectively [17,19,21]. In a study from
Germany, the age-adjusted incidence of PV was 9-fold
higher in patients with a migration background, compared
with native Germans, emphasizing the geographical and
thus genetic background of the disease [22]. Of all the
pemphigus group patients, PV was the most common
subgroup in our study, with a 90% incidence rate (PF 8%
and PE 1,44%, the least frequent form of pemphigus).
Our findings on PV being the most frequent type are also
compatible with the rates of most other countries such
as India [23], South Korea [24], Bangladesh [25], Saudi
Arabia [26], Kuwait [6], Iran [27] Israel [28], South Africa
[29], Bulgaria [14], Serbia, Montenegro [30], Macedonia
[2], Croatia [31], Greece [32], Italy [33], Germany [12],
Spain [34], and France [17]. This was also true for the UK,
Switzerland, and Singapore [1,4,13]. On the other hand,
there are some notable, exceptional regions such as Tunisia
[17], Mali [35], South Africa [29], Brazil, and other Latin
American countries [36,37] where fogo selvagem, an
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endemic form of PF predominated. In Finland [16], PE
was the most common type of pemphigus and, in Morocco
[38], equal frequencies of superficial and deep forms of
pemphigus were observed. The mean age of 51.4 years old
for PV patients in this report, as well as those in previous
studies, is relatively low compared to mean ages reported
in South Korea [24], Japan [39], and in most European
countries where the disease is reported to present in
the 6th and 7th decades of life. According to a study
conducted in Serbia, when age-specific incidence rates are
calculated, the incidence of PV among women (compared
to men) remains higher until the age of 80 years or older,
after which the incidence for men becomes slightly higher
[40]. Our results of mean age are close to the reports from
Iran [27], Saudi Arabia [26], South Africa [29], Singapore
[41], and other studies conducted in Turkey [11].
However, the mean age of PV patients was lower than in
our study group in Kuwait and India, with a presentation
usually in the 4th decade of life [6,23]. In the present
study, the number of women with PV outnumbered that
of men (195 vs. 151, with a ratio of 1:4); which concurs
with data from most previous studies worldwide, except
for countries with a male predominance such as Saudi
Arabia [26], Kuwait [6], Bangladesh [25], and China [9].
In this study, common comorbidities were hypertension,
diabetes, hyperlipidemia, and osteoporosis, observed
in 7%, 4%, 2.5%, and 2,5% of the patients, respectively.
Frequent comorbidities for this patient population are
cardiovascular diseases, concomitant malignancies,
diabetes, and neurological disease, according to various
studies [1].
High-quality controlled prospective clinical trials
for the treatment of autoimmune blistering diseases are
rare; therefore, treatment decisions are mainly guided
by published reviews in this field or from personal
experiences. In our clinical practice, all of the patients
with PV were started on high-dose systemic steroids (1–
1.5 mg/kg/day of methylprednisolone), together with at
least one immunomodulatory adjuvant, most commonly
azathioprine or mycophenolate, in order to minimize the
adverse effects of steroid therapy. Pulse steroid therapy,
rituximab, and IVIg are treatments of choice in case of
relapse. Our mean initial systemic steroid dose in this
study was 100 mg/day of methylprednisolone. However,
especially in Western countries, treatment approaches
are less aggressive, with lower doses of systemic steroids
for shorter periods and occasionally with adjuvants
[1]. This is probably due to the milder course of disease
in these populations. In our patient group, 20% had
at least 3 infusions of pulse steroid therapy, 11% used
either rituximab or IVIg, and 13% used these 2 agents
in combination. In total, almost half of our PV patients

(44%) experienced relapses despite conventional steroids,
in addition to adjuvant agents and required advanced
treatment approaches for their recalcitrant disease.
During the clinical course of PV, relapses are frequent and
inevitable [42]. Almost half of the patient population (N:
100) had recurrent attacks. However, the rates of recurrence
were significantly lower in the IVIg and rituximab groups
(23% and 7%, respectively), similar to the literature [43]. It
is important to consider the acute and chronic side effects
of high-dose steroid infusions such as hypertension,
hyperglycemia, fluid and electrolyte imbalances, sleep
disturbances, mood alteration, and psychosis. Avascular
necrosis of the hip, cardiac arrhythmias, cardiac arrest,
and sudden death are rare but notable.
4.2. Pemphigus foliaceus
In the case of PF, autoantibodies against desmoglein 1
result in superficial subcorneal blisters without mucosal
involvement. PF was the 3rd most common AIBD,
occurring at a frequency of 6.6%. It has been reported less
frequently than PV worldwide, except in endemic areas of
the world such as Brazil, North Africa, Tunisia, and Algeria
[44]. A study [17] comparing the rate of incidence of PV
in France and Tunisia showed a higher incidence rate in
the former (6.7 vs. 1.7 new cases per million people per
year), especially for PF occurring in young women. This is
possibly related to exposure to risk factors that are either
more prevalent in or more often expressed among young
women living in particular areas of Tunisia. Another
prospective study [45] found a significant association of
PV occurring in young women from traditional Tunisian
backgrounds who came into contact with ruminants,
cut and handled raw poultry, had Turkish baths, or used
cosmetics. The mean age and sex ratio of PF were close to
those of PV in our study. (49.4 vs. 54.4)
4.3. Bullous pemphigoid
This ailment is characterized by autoantibodies against
hemidesmosomes at dermoepidermal junction, and
it presents with subepithelial blisters and, sometimes,
urticarial plaques. In the present study, BP ranked 2nd
in frequency among AIBDs, although it was much less
common than PV (13% vs. 70%). The ratio of BP to PV has
been reported to be 1:5.4, which is similar to ratios found
in Singapore (3:1) and in a previous study conducted in
Turkey (1:5.1) [11,13]. Unlike Turkey and other Eastern
countries such as Kuwait, China, Iran, and Malaysia, this
ratio is completely different in Europe [6,9,10].
Subepidermal AIBDs represent about 60% to 70% of all
AIBD cases in Germany and France, with an incidence rate
of 13.4 and 10.4 cases per year and per million inhabitants,
respectively [22,46]. Similar results were also observed in
Switzerland and the UK [1,4]. Compared to epidemiologic
surveys in different parts of the world, the incidence of BP
in Turkey is higher than that of neighboring Romania and
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Kuwait [6]. By contrast to the various studies mentioned
above, the incidence of BP in different countries shows
an opposite pattern, with 3–20 times higher values in
Western European and Asian countries such as Germany,
Italy, Switzerland, Scotland, Finland, Poland, the USA,
Singapore, France, and the United Kingdom, where
the incidence of BP is the highest (42.8 pmp/year)
[1,4,12,13,47–54]. According to a very recent study, Serbia
is the only country with similar average crude and ageadjusted incidence rates for both PV and BP [40].
The incidence rate of BP, especially in Western
countries, progressively and significantly increases with
age, particularly after the age of 70, with a peak after 90
years old [40]. The incidence rate appears to be higher in
women until the age of 70 but, thereafter, the incidence
is higher in men [1]. The mean age of presentation for
BP in our study was 75.6 years old, which is significantly
higher than PV, as expected. The lower incidence of BP
and lower mean age of affected patients may reflect the
paucity of the elderly population in less industrialized
countries. Nevertheless, the possibility that different
genetic or environmental factors may play some role in the
disease profile cannot be ruled out. It must be noted that
in most of these studies, only absolute numbers of patients
were reported and not sex-specific incidence rates. In the
present study, the highest incidence rates of pemphigoid
for both sexes were registered in age groups 70–79 years
old and particularly in individuals 80 years or older, which
is in accordance with the literature.
In our study, women were affected 1.25 times more
often than men, which corresponds to results from other
countries, except for Kuwait, which showed an even more
pronounced female predominance (up to 6 times). Female
predominance has been reported worldwide for BP, except
in China and Germany [9,47]. Male predominance was
also reported in the elderly population after adjusting for
sex in another recent study from Germany [12].
The most frequently observed comorbidities in BP
patients in our study were hypertension and diabetes
mellitus, followed by Alzheimer’s disease at 29%, 13%, and
7% respectively, similar to other studies [55]. According
to a study conducted in the United States, cardiovascular
diseases were the most frequently associated health
problem, affecting more than half of patients. Neurological
diseases, malignancies, atopic diseases, chronic kidney
failure, and diabetes were also common, similar to our
cohort [56]. There are many studies in the literature
establishing an association between BP and a higher
prevalence of neurological disorders, namely dementia
and cerebral stroke, when compared with the general
population. In France, 36% of BP patients were diagnosed
with at least 1 neurological disorder, namely dementia,
in 20% of BP patients [57]. However, lacking a control
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population, it was not possible for this study to confirm
or reject the association of BP with neurological diseases,
especially with the cases of Parkinson’s disease, dementia,
and multiple sclerosis reported in previous studies [58,59].
Chuang et al reported an association between BP and
diabetes, showing 20% diabetic BP patients versus 2.5%
diabetic controls (P = 0.004). This was supported by
other studies. It has been proposed that an autoimmune
response occurs after exposure to BP antigens by glycation
of proteins of the dermoepidermal junction [60].
Considering the overall, advanced age of this population,
the observed association between both cardiovascular and
neurological diseases is not surprising.
Notably, of the patients with BP, 71% were treated with
systemic steroids only, and the mean initial corticosteroid
dose required to control the disease symptoms was
relatively lower than in the PV group (60 mg/day vs. 100
mg/day of methylprednisolone). The steroid dose was
also tapered more quickly. In 17 cases (38%), systemic
immunosuppressive drugs such as azathioprine, dapsone,
and methotrexate were used as adjuvants. The main side
effects observed during therapy were steroid-related, like
osteoporosis and myopathy.
4.4. Other bullous disorders
MMP represented 0.86% of ABDs. This percentage may
also reflect an underestimation of the incidence of this
disease because many patients are diagnosed and seen by
dentists and ophthalmologists.
EBA, in the group of mechanobullous disorders, was
diagnosed in 2.02% of patients by DIF on salt-split skin.
It was predominantly seen in men, as it was in Germany,
Singapore, and China [9,12,13].
Thirteen patients (3.7%) were diagnosed as LAD. This
finding may also reflect an underestimation, as we suppose
that a significant proportion of such patients may have been
diagnosed by pediatricians. Only 1 patient had a mucosal
involvement, while the remainder had cutaneous lesions.
Actually, this outcome is not compatible with studies found
in the literature that say mucosal involvement occurs in
up to 80% of patients [40]. One patient had accompanying
ulcerative colitis, which is the most common disease
associated with LAD.
We were unable to accurately estimate the incidence
and prevalence rates of bullous diseases in Turkey or in
İstanbul according to the results of our study, although
our clinic is the leading referral center for bullous diseases
in the country. The lack of a central registry for bullous
diseases and the limited number of other minor clinics or
private practitioners covering the same patient population
make this goal impractical at present.
PV was the most frequent AIBD according to our
study; cases of PV outnumbered those of BP by a ratio
of almost 5:1. This contrasts with findings from Western
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European countries, where BP predominates. Female
predominance was found in the patient profile for most
subtypes of AIBD. The mean age at onset of PV and BP was
lower in Turkey than in Europe and higher than in some
Middle Eastern countries. Almost half of our PV patients
were recalcitrant and required advanced treatment
options, demonstrating the hard-to-control nature of the
disease. Given the country’s large number of PV patients,
future clinical trials regarding the efficacy and side effects
of treatment options can be conducted in Turkey. Future
studies may reveal additional information on patterns of

incidence with respect to the entire spectrum of AIBDs in
different areas of the world.
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